Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yu Ri | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Oh, Suk-Joong | - |
dc.contributor.author | Yoon, Sung -Soo | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Oh, Sung Young | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Nam, Seung Hyun | - |
dc.contributor.author | Shim, Hyeok | - |
dc.contributor.author | Park, Joon Seong | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.date.accessioned | 2023-12-15T15:10:32Z | - |
dc.date.available | 2023-12-15T15:10:32Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.issn | 2005-9256 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89611 | - |
dc.description.abstract | Purpose This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL).Materials and Methods Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R -CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy.Results Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent >= grade 3 adverse events (40.0%) and five treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016).Conclusion Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients (ClinicalTrials.gov ID: NCT01054781). | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.title | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | - |
dc.type | Article | - |
dc.identifier.wosid | 001087738400028 | - |
dc.identifier.doi | 10.4143/crt.2023.271 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.55, no.4, pp 1355 - 1362 | - |
dc.identifier.kciid | ART003005746 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85175118829 | - |
dc.citation.endPage | 1362 | - |
dc.citation.startPage | 1355 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 55 | - |
dc.citation.number | 4 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.subject.keywordAuthor | Diffuse large B -cell lymphoma | - |
dc.subject.keywordAuthor | R -CHOP | - |
dc.subject.keywordAuthor | Response | - |
dc.subject.keywordPlus | CHOP-LIKE CHEMOTHERAPY | - |
dc.subject.keywordPlus | DOSE-DENSE RITUXIMAB | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | NON-HODGKIN-LYMPHOMA | - |
dc.subject.keywordPlus | YOUNG-PATIENTS | - |
dc.subject.keywordPlus | R-CHOP | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | MALE GENDER | - |
dc.subject.keywordPlus | DLBCL | - |
dc.subject.keywordPlus | OPTIMIZATION | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.